Drugs / recombinant asparaginase
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00983138 | Jul 2009 → Feb 2011 | acute lymphoblastic leukemia | medac GmbH | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | recombinant asparaginase | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00983138 ↗ |
| Known as | rASNase | “pharmacodynamics of recombinant ASNase (rASNase) for first-line treatment” NCT00983138 ↗ |
| Route | Intravenous | “6 i.v. infusions” NCT00983138 ↗ |